Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Vaccine Formulations
NCT07089706Phase 4Completed
- Sponsor
- Moderna Inc
- Start
- Jul 2025
- Primary completion
- Jun 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of mRNA-1283.251 in coronavirus disease 2019 (COVID-19), sponsored by Moderna Inc. Started Jul 2025; status: completed.
02
Drugs
mRNA-1283.251
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07089706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07089706.